

IV ème CONGRÈS EUROPÉEN DE L'ANTEL

Association Nationale de Télémédecine

■ ATELIER EUROPÉEN/EUROPEAN WORKSHOP

Rôle de la télémédecine et des systèmes d'information dans la sécurité des patients en Europe/The Role of Telemedicine and Information Systems for Patient Safety in Europe

- Système de prescription électronique en Andalousie pour améliorer la sécurité des patients
Integrated information and health care management support system and patient safety in Andalusia.
Dr J.L. Rocha, Vice-Président du Réseau ENRICH, Ministère Régional de la Santé en Andalousie (Espagne) / Vice-President of the ENRICH network, Regional Ministry of Health of Andalusia (Spain)

José L. ROCHA
General Secretary for Quality and Modernisation
Regional Ministry of Health
Government of Andalusia, Spain
josel.rocha@juntadeandalucia.es



Andalusia

8,302,923 inhabitants

87,597 Km²




Andalusian Public Healthcare System: Main features

1,146	Primary care centers
360	Auxiliary offices for primary care
49	Public Hospitals (16,821 beds)
102,000	Healthcare professionals
9,390 M €	Health Budget 2011, 6.67% GDP




The Digital Strategy of the Public Healthcare System of Andalusia: The *Diraya* Project


- A **long-term** Strategy: From 1999
- A single **health record number** for all citizens of Andalusia
- A single **electronic Health Record** for every person
- A individual **smart card** for each person as a key for access
- A **regional eHR** shared among:
 - Primary care
 - Pharmacies
 - Hospitals
 - Emergencies




Much more than an eHR: A corporate information system




Functional architecture of the eHR in Andalusia



De-centralised structure for Hospitals: Admission, Clinical Stations for inpatients, outpatients and emergencies. Internal Local Bus for connecting tools: Lab tests, Functional tests, PACs, Pathology...



Central Bus for Hospital-Primary Care connection, data exchange and shared tools: lab module, RIS/PACs, Referrals. Also for some centralised tools: surgical waiting list, etc



Centralised electronic Clinical Station and tools for primary care: appointment, e-prescription, vaccines



Centralised (duplicated) substructure: Citizens data base, Operators Module, Resources Structure



Centralised replicated database for data mining, indicators and evaluation reports

Current extension of the eHR in Andalusia

Completion level	Tool	Population	Cases in 2010
	Clinical Station	100%	7.9 M Pat / 39.7 M Sheets
	Appointment	100%	83 Million
	Referral tool	100%	39.7 Million
	e-Prescription	99.8%	105 Million
	Radiology (RIS)	71%	3.4 Million
	Lab tests	49%	360,000
	Clin Station - Hosp. Emergencies	100%	3.4 Million
	Clinical Station – Outpatients	100%	1.5 Million
	Clinical Station – Inpatients	26%	916,890
	Admission	18%	60,000
	Appointment	100%	12 Million
	e-Prescription	56%	505,862
	Lab tests	25%	
	Radiology (PACS)	29%	3.4 Million
	Out of Hosp. Emergencies	20%	


ePrescription module: “*Receta XXI*”



Smart card as a key





Instruction sheet for patient



*Intranet of the
Andalusian Public
Healthcare System*


Treatment available on line



*Intranet of the
Official College of
Pharmacists*


The system allows the dispensation of the treatment during the time established by the doctor at any pharmacy

Use of the e-Prescription module in Andalusia




Number of e-Prescriptions in the Andalusian Public Healthcare System
from 2004 to 2010

Use of the e-Prescription module in Andalusia




Percentage of the different types of prescription in the Andalusian Public Healthcare System from 2004 to 2010

Use of the e-Prescription module: primary care appointments after introducing this module




6 months trial with the same cohort of population

Use of the e-Prescription module: % of prescriptions done by INN (international nonproprietary name) and estimated savings



Use of the e-Prescription system in Andalusia: cumulative economic performance




Case studies. European Comission. <http://www.ehr-impact.eu/cases/cases.html>

07/2009 The socio-economic impact of Receta XXI, the regional ePrescribing system of Andalucía's public health service. http://www.ehr-impact.eu/cases/documents/EHRI_case_Receta_XXI_final.pdf

Much more than an e-Prescription module: a Decision support system

- Single medicines record
- Updated catalogue (Nomenclator)
- Prescription by International Nonproprietary Name
- Help in filling up dosage
- Warnings for duplicated prescription
- Evidence-based guide by Medical Primary Care Society
- Info on drugs
- Allergies and contraindications
- Help reporting adverse reactions
- Interactions
- Warning maximum daily doses
- Warning therapeutic redundancy
- Forms included

Medical decision support system: selection of the recommended treatment from the approved Guidelines



Medical decision support system: selection of the active principle (INN) vs. commercial brand

PIÑA VERA, MARIA JOSE (Pozoblanco)-HISTORIA DE SALUD DIGITAL DEL CIUDADANO - Centro de atención primaria-Historia de salud de un usuario - [Medicación de usu]

Atención al usuario Atención clínica Historias Profesionales y agendas Consultas generales Pruebas Analíticas Ayuda Salir

His Medicación de: Edad: 46 Sexo: Mujer Prescripción Diraya v. 4.4.02 Nomenclátor 05/2010 Farmacia normal

Histórico de fármacos LT Nueva prescripción Visado

Nombre comercial: PLAVIX

Principio activo

Nombre comercial

Nombre comercial	P.V.P (€)	ATC	VI	Max env.	Visado	Novedad terapéutica
PLAVIX 75MG 28 COMPRIMIDOS RECUBIERT	57,68	INHIBIDORES DE LA AGREGACION PLA		1	<input checked="" type="checkbox"/>	

Buscar

Información acerca del medicamento

1 envase máximo por receta

Prescripción por principio activo

Composición	Precio menor
CLOPIDOGREL 75MG, 28 COMPRIMIDOS	39

Prescripción por nombre comercial

Especialidades	P.V.P(€) facturación
PLAVIX 75MG 28 COMPRIMIDOS RECUBIERTOS PELICULA	57,68
CLOPIDOGREL BEXALABS 75MG 28 COMPRIMIDOS RECUBIERT	27,3
CLOPIDOGREL SANDOZ 75MG 28 COMPRIMIDOS RECUBIERTOS	27,3
CLOPIDOGREL ACTAVIS 75MG 28 COMPRIMIDOS RECUBIERTO	39
CLOPIDOGREL ARROW 75MG 28 COMPRIMIDOS RECUBIERTOS	39
CLOPIDOGREL HCS 75MG 28 COMPRIMIDOS RECUBIERTOS CO	39
CLOPIDOGREL KERN PHARMA 75MG 28 COMPRIMIDO RECUBIE	39
CLOPIDOGREL LESVI 75MG 28 COMPRIMIDOS RECUBIERTOS	39
CLOPIDOGREL MYLAN 75MG 28 COMPRIMIDOS RECUBIERTOS	39
CLOPIDOGREL NEREDAL 75MG 28 COMPRIMIDOS RECUBIERTO	39
CLOPIDOGREL QUALIGEN 75MG 28 COMPRIMIDOS RECUBIERT	39
CLOPIDOGREL RATIOQUADRUM 75MG 28 COMPRIMIDOS REC	39

Valor intrínseco elevado

Incluir volante prescripción tra

RXXI Imp Fe

Presc

Medical decision support system: avoid a drug already prescribed in the current treatment by other doctor

PIÑA VERA, MARIA JOSE (Adra)-HISTORIA DE SALUD DIGITAL DEL CIUDADANO - Centro de atención primaria-Historia de salud d...

Atención al usuario Atención clínica Historias Profesionales y agendas Centro Consultas generales Ayuda Salir

His Medicación de: Edad: 44 años Sexo: Mujer Farmacia normal

Histórico de fármacos LT Nueva prescripción Visado

Principio activo Dosis Vía de administración

Nombre comercial Principio activo Dosis Vía de administración

Nombre comercial	Principio activo	Dosis	Vía de administración
CIPROFLOXACINO 3MG/G 3,5G POMAD	CIPROFLOXACINO	4,48	OTROS ANTIINFECCIOSOS
CIPROFLOXACINO 3MG/ML 5ML COLIR	CIPROFLOXACINO	4,64	OTROS ANTIINFECCIOSOS
CIPROFLOXACINO 3MG/ML 5ML GOTAS	CIPROFLOXACINO	6,46	ANTIINFECCIOSOS

Buscar

Nombre presentación P.M.A (€) Grupo terapéutico VI Max env Visado Novedad terapéutica

CIPROFLOXACINO 3MG/G 3,5G POMAD 4,48 OTROS ANTIINFECCIOSOS A 1

CIPROFLOXACINO 3MG/ML 5ML COLIR 4,64 OTROS ANTIINFECCIOSOS A 1

CIPROFLOXACINO 3MG/ML 5ML GOTAS 6,46 ANTIINFECCIOSOS A 1

Historia de Salud

El paciente está en tratamiento con los siguientes medicamentos que contienen también el principio activo CIPROFLOXACINO:

Medicamentos Crédito para x días
CIPROFLOXACINO 250MG, 20 COMPRIMIDOS 10

¿Desea prescribir el medicamento?.

Imprimir hoja de instrucciones

Sí No


RXXI Imp Fecha Nombre comercial Cant D.Cant N-Ud. Causa Unidad D.Trat días D.Env N°e

Prescripción por Receta RXXI por defecto.


Guardar Aceptar Cancelar

TA

% of unnecessarily repeated drugs avoided in elderly patients receiving multiple medication after the introduction of a Medical Decision Support System for prescription



Medical decision support system: detection of pharmacological interactions between drugs



Medical decision support system: detection of allergies or previous intolerance to drugs

PIÑA VERA, MARIA JOSE (Adra)-HISTORIA DE SALUD DIGITAL DEL CIUDADANO - Centro de atención primaria-Historia de salud d...

Medicación de usuario

Medicación de: TALLON ARJONA, ESTHER Edad: 44 años Sexo: Mujer Farmacia normal

Histórico de fármacos | LT | Nueva prescripción | Visado |

Principio activo

Nombre comercial

Nombre comercial: CLAMO

Buscar

Nombre comercial	P.V.P (€)	Grupo terapéutico	VI	Max env	Visado	Novedad terapéutica
CLAMOXYL IM 1G/VIAL 1 INYECTABLE	2,09	PENICILINAS CON ESPECTRO AMPLIA	4	<input type="checkbox"/>		
CLAMOXYL IM 500MG/VIAL 1 INYECTABLE	1,25	PENICILINAS CON ESPECTRO AMPLIA	4	<input type="checkbox"/>		
CLAMOXYL MUCOLITICO 250/4 60ML SUSP	5,07	EXPECTORANTES Y/O MUCOLÍTICOS B	1	<input type="checkbox"/>		
CLAMOXYL MUCOLITICO 500/8 12 CAPSUL	6,02	EXPECTORANTES Y/O MUCOLÍTICOS B	1	<input type="checkbox"/>		
CLAMOXYL 1G 12 COMPRIMIDOS	3,36	PENICILINAS CON ESPECTRO AMPLIA	2	<input type="checkbox"/>		
CLAMOXYL 1G 24 COMPRIMIDOS	6,63	PENICILINAS CON ESPECTRO AMPLIA	2	<input type="checkbox"/>		

Historia de Salud

El paciente tiene alergia al principio activo AMOXICILINA y el fármaco prescrito lo contiene.

Aceptar Cancelar

Seleccionar 08/2006

Imprimir hoja de instru

RXXI Imp Fecha Número comercial Cant D.Cant N-UU Cada Unidad D.Trat días D.Env N°e

ePrescription module: Role of the pharmacist




Pharmacist can send an alert to the individual eHR and block a prescription until the Doctor can check it and confirm or not

Medicación del paciente		Descripción Delyra v. 4.4.0		Número de alta: 01/2010		Edad: 46		Sexo: Mujer		Firma digital		Visado													
<input type="checkbox"/> Historial de fármacos LT Nueva prescripción Visado																									
<input type="checkbox"/> Medicación activa del usuario																									
Prescripción:	Terapéutica:	Ex:	Frecuencia:	Uso:	Período:	Fecha primera:	Fecha última:	Expiración:	RMA:																
PRE-GASALINA 7MG 56 CAPSULAS						11 CAPSULA/12 Horas	15/02/2010	16/02/2010																	
PRE-GASALINA 2MG 56 CAPSULAS						1 GOTAL/51 Horas	02/02/2010	01/03/2011																	
FLUODASA GOTAS 1 FRASCO DE 30ML						1 SOBRE/72 Horas	02/02/2010	01/03/2011																	
OMEPRAZOL 20MG 28 CAPSULAS						1 COMP/12 Horas	02/02/2010	01/03/2011																	
ELEMENTAL ANTI-ATR 2000/12 101 G E SOBRES						1 COMP/12 Horas	02/02/2010	01/03/2011																	
CARBAMAZEPINA ALTA TER 400MG 100 COMP EF						1 COMP/12 Horas	02/02/2010	01/03/2011																	
CARBAMAZEPINA ALTA TER 400MG 100 COMP EF						1 COMP/12 Horas	02/02/2010	01/03/2011																	
CARBAMAZEPINA ALTA TER 400MG 50 COMP EF						1 COMP/12 Horas	02/02/2010	01/03/2011																	
CARBAMAZEPINA ALTA TER 200MG 50 COMP EF						1 COMP/12 Horas	02/02/2010	01/03/2011																	
SODIO VEGETAL BAJA FRESCON HOMBRES 10L						1 UNIDAD/72 Horas	07/02/2010	17/08/2010																	
DIAMORON 80MG 20 COMPRIMIDOS						1 COMP/12 Horas	07/02/2010	17/08/2010																	
OMEPRAZOL 20MG 14 CAPSULAS						1 CAPSULA/12 Horas	07/02/2010	17/08/2010																	
EL 4000/12 101 G E SOBRES						1 COMP/12 Horas	02/02/2010	01/03/2011																	
ANSORIENTE INICIO DESNA DIA ANATO ELIA						1 UNIDAD/24 Horas	05/02/2010	05/02/2010																	
OMEPRAZOL 20MG 26 CAPSULAS						1 CAPSULA/24 Horas	07/02/2010	26/07/2010																	

Intranet of the Official College of Pharmacists



Intranet of the Andalusian Public Healthcare System



Confirmed Re-activated



Medical office

A warning appears at the patient's eHR and Doctor can check the comments from the pharmacist and confirm this criteria or maintain the drug

The electronic prescription as a tool for improving patient safety



The Andalusian Strategy for improving Patient Safety


Adverse events are a main cause of mortality and morbidity.

In Andalusia 6.93% of hospitalized patients and 1.01% of primary care patients have an adverse event (ENEAS Study, 2005 and APEAS Study, 2006)

28.8% of adverse events in medical areas in Andalusia are drug-related

Electronic prescription tools may play a tremendous role improving patient safety throughout the entire healthcare process, avoiding mistakes in denomination and dosage, duality, interactions or incompatibilities, checking for previous allergies and intolerance

Furthermore, e-prescription systems can facilitate the collaborative work between pharmacists, doctors and other professionals, and provide information about drug compliance.



PARIS
17-18 NOVEMBRE 2011
ESPACE ST MARTIN

LA TÉLÉMÉDECINE
pour une prise en charge améliorée du patient.
Perspectives en France et en Europe
TELEMEDICINE
Improving patient management
Perspectives in France and Europe

IV ème CONGRÈS EUROPÉEN DE
L'ANTEL
Association Nationale de Télémédecine

■ ATELIER EUROPÉEN/EUROPEAN WORKSHOP

Rôle de la télémédecine et des systèmes d'information dans la sécurité des patients en Europe/The Role of Telemedicine and Information Systems for Patient Safety in Europe

- Système de prescription électronique en Andalousie pour améliorer la sécurité des patients
Integrated information and health care management support system and patient safety in Andalusia.
Dr J.L. Rocha, Vice-Président du Réseau ENRICH, Ministère Régional de la Santé en Andalousie (Espagne) / Vice-President of the ENRICH network, Regional Ministry of Health of Andalusia (Spain)

Thank you very much!

Merci beaucoup!